Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Therapeutic Drug Monitoring in GIST
NCT05493215Phase 2Recruiting
- Start
- Mar 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in gastrointestinal stromal tumor (GIST). Primary endpoint: Incidence of Grade 3/4 adverse events attributable to imatinib per CTCAE v5.0 at 6 months. Started Mar 2024; status: recruiting.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05493215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493215.